Scarica l'app Stockscreener
0.753
4.13%
-0.0324
Precedente Chiudi:
$0.7854
Aprire:
$0.771
Volume 24 ore:
15,211
Relative Volume:
0.01
Capitalizzazione di mercato:
$3.07M
Reddito:
-
Utile/perdita netta:
$-7.35M
Rapporto P/E:
-1.637
EPS:
-0.46
Flusso di cassa netto:
$-5.48M
1 W Prestazione:
-15.10%
1M Prestazione:
-12.34%
6M Prestazione:
+88.30%
1 anno Prestazione:
+92.93%
Intervallo 1D:
$0.75
$0.798
Intervallo di 1 settimana:
$0.7301
$0.9099
Portata 52W:
$0.2872
$3.30
Shuttle Pharmaceuticals Holdings Inc Stock (SHPH) Company Profile
Nome
Shuttle Pharmaceuticals Holdings Inc
Settore
Telefono
(240) 403-4212
Indirizzo
401 PROFESSIONAL DRIVE, GAITHERSBURG
Confronta SHPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SHPH
Shuttle Pharmaceuticals Holdings Inc
|
0.753 | 3.07M | 0 | -7.35M | -5.48M | -0.46 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Shuttle Pharmaceuticals Holdings Inc Borsa (SHPH) Ultime notizie
Shuttle Pharmaceuticals expands glioblastoma trial - MSN
Form 424B3 Shuttle Pharmaceuticals - StreetInsider.com
BlackRock MuniHoldings New York Quality Fund Enters Standstill Agreement with Saba Capital Management - Defense World
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Shuttle Pharma hits 25% mark in glioblastoma trial - MSN
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug - StockTitan
Form S-1 Shuttle Pharmaceuticals - StreetInsider.com
Shuttle Pharmaceuticals (NASDAQ:SHPH) Faces Potential Delisting from Nasdaq due to Minimum Bid Price Requirement Noncompliance - Defense World
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - The Manila Times
Shuttle Pharmaceuticals CEO to Present Glioblastoma Trial Updates at Lytham Partners Healthcare Summit - StockTitan
Tilray (TLRY) Stock Drops 5.11% Amidst Market Volatility - GuruFocus.com
EZFill Holdings, Inc. Enters Mobile Fueling Vendor Agreement with Amazon - Defense World
Shuttle Pharmaceuticals Holdings, Inc. Engages in Sponsored Research Agreement with UCSF - Defense World
Shuttle Pharma Enters into Sponsored Research Agreement - GlobeNewswire
Shuttle Pharmaceuticals Partners with UCSF for Breakthrough Prostate Cancer Diagnostic Development - StockTitan
Shuttle Pharmaceuticals stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada
SHPH stock touches 52-week low at $0.75 amid market challenges - Investing.com UK
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA - GuruFocus.com
Likelihood of Approval and Phase Transition Success Rate ModelRopidoxuridine in Bile Duct Cancer (Cholangiocarcinoma) - GlobalData
Shuttle Pharmaceuticals Initiates Phase 2 Clinical Trial for Glioblastoma Treatment- - Defense World
Shuttle Pharmaceuticals stock hits 52-week low at $0.83 By Investing.com - Investing.com Canada
Shuttle Pharma Expands Patient Enrollment for Phase 2 - GlobeNewswire
Shuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma - TipRanks
Shuttle Pharmaceuticals Launches Phase 2 Trial for Breakthrough Glioblastoma Treatment | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Up - GuruFocus.com
Micro Cap Company Is Soaring On Phase 2 Trial Update - MSN
500: Something went wrong - Investing.com UK
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Shuttle Pharma Provides Third Quarter 2024 Corporate Update - GlobeNewswire
Shuttle Pharma Advances Phase 2 Trial, Secures $4.5M Funding for Cancer Treatment Study | SHPH Stock News - StockTitan
Shuttle Pharmaceuticals’ $4.5 Million Common Stock Offering - Global Legal Chronicle
Top 3 Penny Stocks to Watch Today – October 31, 2024 - The Global Domains News
Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com
Shuttle Pharma (SHPH) Stock Surges on Clinical Trial, Financing and Debt Elimination News - MSN
Shuttle Pharma Raises $4.5M for Clinical Trials - TipRanks
3 Penny Stocks to Watch Now, 10/31/24 - TipRanks
Shuttle Pharmaceuticals Successfully Doses First Patients in Phase 2 Clinical Trial for Glioblastoma Treatment - Defense World
Shuttle Pharma doses three subjects in Phase II glioblastoma treatment trial - Yahoo! Voices
"Stocks Key Trendlines: PRSO, PFIE, SHPH, BKYI, LIXT on the Verge of Breakthroughs" - Marketscreener.com
SHPHShuttle Pharmaceuticals Holdings, Inc. Latest Stock News & Market Updates - StockTitan
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Shuttle Pharmaceuticals dips 6%, prices $3.5M share offering - MSN
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of - GlobeNewswire
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Benzinga
Shuttle Pharma Pays Off Senior Secured Convertible Note - GlobeNewswire
Shuttle Pharmaceuticals Holdings Inc Azioni (SHPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):